Bridging between transplantation therapy and neurotrophic factors in Parkinson's disease

Frontiers in Bioscience - Elite

Volumn 6 E, Issue 2, 2014, Pages 225-235

  Ghosh, Biswarup ^a   Zhang, Chen ^b   Smith, George M ^a  

^a TEMPLE UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Dopamine; Netrin; Neurotrophins; Parkinson's disease; Review; Transplants

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; NEUROTROPHIC FACTOR; NEURTURIN;

ASSOCIATION; CLINICAL TRIAL (TOPIC); DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG TARGETING; HUMAN; MESENCEPHALON; MOLECULAR PATHOLOGY; NERVE FIBER; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; REVIEW; STEM CELL TRANSPLANTATION; SUBSTANTIA NIGRA;

CELL TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; DOPAMINERGIC NEURONS; GENE TRANSFER TECHNIQUES; HUMANS; NERVE GROWTH FACTORS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 84904506946     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/e704     Document Type: Review

References (128)

1. I. Mendez, R. Sanchez-Pernaute, O. Cooper, A. Vinuela, D. Ferrari and L.Bjorklund: Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128, 1498-1510 (2005)
2. J. H. Kordower, T. B. Freeman, B. J. Snow, F. J. Vingerhoets, E. J. Mufson and P. R. Sanberg: Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 332, 1118-1124 (1995)
3. J. H. Kordower, T. B. Freeman, E. Y. Chen, E. J. Mufson, P. R. Sanberg and R. A. Hauser: Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Mov Disord 13, 383-393 (1998)
4. P. Piccini, O. Lindvall, A. Bjorklund, P. Brundin, P. Hagell and R. Ceravolo: Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 48, 689-695 (2000)
5. C. R. Freed, P. E. Greene, R. E. Breeze, W. Y. Tsai, W. DuMouchel and R. Kao: Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344, 710-729 (2001)
6. C. W. Olanow, C. G. Goetz, J. H. Kordower, A. J. Stoessl, V. Sossi and M. F, Brin: A doubleblind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54, 403-414 (2003)
7. H. Bernheimer, W. Birkmayer, O. Hornykiewicz, K. Jellinger and F. Seitelberger: Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20, 415-455 (1973)
8. A. E. Lang and A. M. Lozano: Parkinson's disease. First of two parts. N Engl J Med 339, 1044-1053 (1998)
9. I. N. Miller, and A. Cronin-Golomb:Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov Disord 25, 2695-2703 (2010)
10. C. C. McCulloch, D. M. Kay, S. A. Factor, A. Sami, J. G. Nutt, D. S. Higgins, A. Griffith, J. W. Roberts, B. C. Leis, J. S. Montimurro, C. P. Zabetian and H. Payami: Exploring gene-environment interactions in Parkinson's disease. Hum Genet 123, 257-265. (2008)
11. W. R. Gibb, and A. J. Lees: Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 54, 388-396 (1991)
12. M. H. Polymeropoulos, J. J, Higgins, L. I. Golbe, W. G. Johnson, S. E. Ide, G. Di Iorio, G. Sanges, E. S. Stenroos, L. T. Pho, A. A. Schaffer, A. M. Lazzarini, R. L. Nussbaum and R. C. Duvoisin: Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science 274, 1197-1199 (1996)
13. R. Krüger, W. Kuhn, T. Müller, D. Woitalla, M. Graeber, S. Kösel, H. Przuntek, J. T. Epplen, L. Schöls and O. Riess:. Ala30Pro mutation in the gene encoding alphasynuclein in Parkinson's disease. Nat Genet 18, 106-108 (1998)
14. E, M, Valente, A. R. Bentivoglio, P. H. Dixon, A. Ferraris, T. Ialongo, M. Frontali, A. Albanese and N. W. Wood: Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet 68, 895-900 (2001)
15. C. M. van Duijn, M. C. Dekker, V. Bonifati, R. J. Galjaard, J. J. Houwing-Duistermaat, P. J. Snijders, L. Testers, G. J. Breedveld, M. Horstink, L. A. Sandkuijl, J. C. van Swieten, B. A. Oostra and P. Heutink: Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet 69, 629-634 (2001)
16. A. B. Singleton, M. Farrer, J. Johnson, A. Singleton, S.Hague, J.Kachergus, M. Hulihan, T. Peuralinna, A. Dutra, R. Nussbaum, S. Lincoln, A. Crawley, M. Hanson, D. Maraganore, C Adler, M. R. Cookson, M. Muenter, M. Baptista, D. Miller, J. Blancato, J. Hardy, and K. Gwinn-Hardy. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302, 841(2003)
17. J. J. Zarranz, J. Alegre, J. C. Gómez-Esteban, E. Lezcano, R. Ros, I. Ampuero, L. Vidal, J. Hoenicka, O. Rodriguez, B. Atarés, V. Llorens, E. Gomez Tortosa, T. del Ser, D. G. Munoz and J. G. de Yebenes: The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55, 164-173 (2004)
18. A. Zimprich, S. Biskup, P. Leitner, P. Lichtner, M. Farrer, S. Lincoln, J. Kachergus, M. Hulihan, R. J. Uitti, D. B. Calne, A. J. Stoessl, R. F. Pfeiffer, N. Patenge, I. C. Carbajal, P. Vieregge, F. Asmus, B. Müller-Myhsok, D. W. Dickson, T. Meitinger, T. M. Strom, Z. K. Wszolek and T. Gasser: Mutations in LRRK2 cause autosomaldominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607 (2004)
19. A. Ramirez, A. Heimbach, J. Gründemann, B. Stiller, D. Hampshire, L. P. Cid, I. Goebel, A. F. Mubaidin, A. L. Wriekat, J. Roeper, A. Al-Din, A. M. Hillmer, M. Karsak, B. Liss, C. G. Woods, M. Behrens and C. Kubisch: Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38, 1184-1191 (2006).
20. A. D. Fonzo, M. C. Dekker, P. Montagna, A. Baruzzi, E. H. Yonova, L. Correia, A. Guedes, T. Szczerbinska, L. O. Zhao, C. H. Dubbel-Hulsman, E.de Graaff, W. J. Oyen, E. J. Simons, G. J. Breedveld, B. A.Oostra, M. W. Horstink and V. Bonifati: FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology 72, 240-245 (2009)
21. B. Thomas: Parkinson's disease: from molecular pathways in disease to therapeutic approaches. Antioxid Redox Signal 11, 2077-2082. (2009)
22. T. N. Martinez and J. T. Greenamyre: Toxin Models of Mitochondrial Dysfunction in Parkinson's Disease. Antioxid Redox Signal 16, 920-934 (2012)
23. K. K. Chung, V. L. Dawson and T. M. Dawson: The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci 24, S7-S14 (2001)
24. A. D Owen, A. H. Schapira, P. Jenner and C. D. Marsden: Indices of oxidative stress in Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies. J Neural Transm Suppl 51,167-173 (1997)
25. C. W. Olanow, P. Jenner and D. Brooks: Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 44, S167-S174 (1998)
26. P. Jenner:.Oxidative stress and Parkinson's disease. Handb Clin Neurol 83,507-520 (2007)
27. E. Miyawaki, K. Lyons, R. Pahwa, A. I. Tröster, J. Hubble, D. Smith, K. Busenbark, D. McGuire, D. Michalek and W. C. Koller: Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol. 20, 523-530 (1997)
28. J. A. Obeso, C. W. Olanow and J. G. Nutt: Levodopa motor complications in Parkinson's disease. Trends Neurosci 23, S2-S7 (2000)
29. V. S. Kostcí, J. Marinković, M. Svetel, E. Stefanova, S. Przedborski: The effect of stage of Parkinson's disease at the onset of levodopa therapy on development of motor complications. Eur J Neurol 9, 9-14 (2002)
30. M. Deogaonkar and T. Subramanian: Pathophysiological basis of drug-induced dyskinesias in Parkinson's disease. Brain Res Rev 50, 156-168 (2005)
31. K. Sethi:.Levodopa unresponsive symptoms in Parkinson disease. Mov Disord 23, S521-S533 (2008)
32. E. Tolosa, M. J. Martí, F. Valldeoriola and J. L. Molinuevo: History of levodopa and dopamine agonists in Parkinson's disease treatment. Neurology 50, S2-S10, discussion S44-S18 (1998)
33. A. H. Schapira: Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol 9, 7-14. (2002)
34. S. Fahn: The history of dopamine and levodopa in the treatment of Parkinson's disease. Mov Disord 23, S497-S508 (2008)
35. Y. H. Chen, B. K. Harvey, A. F. Hoffman, Y. Wang, Y. H. Chiang and C. R. Lupica: MPTP-induced deficits in striatal synaptic plasticity are prevented by glial cell line-derived neurotrophic factor expressed via an adeno-associated viral vector. FASEB J 22, 261-275 (2008)
36. D. Kirik, C. Rosenblad, A. Bjorklund and R, J. Mandel: Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci. 20, 4686-4700 (2000)
37. L. Wang, S. Muramatsu, Y. Lu, K. Ikeguchi, K. Fujimoto, T. Okada, H. Mizukami, Y. Hanazono, A. Kume, F. Urano, H. Ichinose, T. Nagatsu, I. Nakano and K. Ozawa: Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene therapy 9, 381-389 (2002)
38. J. H. Kordower, M. E. Emborg, J. Bloch, S. Y. Ma, T. Chu, L. Leventhal, J. McBride, E. Y. Chen, S. Palf, B. Z. Roitberg, W. D. Brown, J. E. Holden, R. Pyzalski, M. D. Taylor, P. Carvey, Z. Ling, D.Trono, P. Hantraye, N. Deglon and P. Aebischer: Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290, 767-773 (2000)
39. J. L. Eberling, A. P. Kells, P. Pivirotto, J. Beyer, J. Bringas, H. J. Federoff, J. Forsayeth and K. S. Bankiewicz: Functional Effects of AAV2-GDNF on the Dopaminergic Nigrostriatal Pathway in Parkinsonian Rhesus Monkeys. Hum Gene Ther. 20, 511-518 (2009)
40. J. D. Elsworth, D. E. Redmond Jr, C. Leranth, K. B. Bjugstad, and J. R. Sladek Jr, T .J. Collier, S. B. Foti, R. J. Samulski, K. P. Vives and R. H. Roth: AAV2-mediated gene transfer of GDNF to the striatum of MPTP monkeys enhances the survival and outgrowth of co-implanted fetal dopamine neurons. Exp Neurol 211, 252-258 (.2008)
41. A. Eslamboli, B. Georgievska, R. M. Ridley, H. F. Baker, N. Muzyczka, C. Burger, R. J Mandel, L. Annett and D. Kirik: Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25, 769-777 (2005)
42. L. C. Johnston, J. Eberling, P. Pivirotto, P. Hadaczek, H. J. Federoff and J. Forsayeth: Clinically relevant effects of AAV2-GDNF on the dopaminergic nigrostriatal pathway in aged Rhesus monkeys. Hum Gene Ther. 20, 497-510 (2009)
43. J, C. Bensadoun, N. Deglon, J. L. Tseng, J. L Ridet, A. D. Zurn and P. Aebischer:. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol. 164, 15-24 (2000)
44. M. Brizard, C. Carcenac, A. P. Bemelmans, C. Feuerstein, J. Mallet and M. Savasta: Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiol Dis, 21, 90-101(2006)
45. E. Dowd, C. Monville, E. M. Torres, L. F. Wong, M. Azzouz, N. D. Mazarakis and S. B. Dunnett: Lentivectormediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model. Eur J Neurosci. 22, 2587-2595 (2005)
46. B. Georgievska, D. Kirik, C. Rosenblad, C. Lundberg and A. Bjorklund: Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13, 75-82 (2002)
47. S. Palfi, L. Leventhal, Y. Chu, S. Y. Ma, M. Emborg, R. Bakay, N. Deglon, P. Hantraye, P. Aebischer and J. H. Kordower: Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic ne2002urons in primate models of nigrostriatal degeneration. J Neurosci 22, 4942-4954 (2002)
48. A. Bilang-Bleuel, F. Revah, P. Colin, I. Locquet, J. J. Robert, J. Mallet and P. Horellou: Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 94, 8818-8823 (1997)
49. X. Chen, W. Liu, Y. Guoyuan, Z. Liu, S. Smith, D. B. Calne and S. Chen: Protective effects of intracerebral adenoviral-mediated GDNF gene transfer in a rat model of Parkinson's disease. Parkinsonism Relat Disord 10, 1-7 (2003)
50. D. L. Choi-Lundberg, Q. Lin, T. Schallert, D. Crippens, B. L. Davidson, Y. N. Chang, Y. L. Chiang, J. Qian, L. Bardwaj and M. C. Bohn: Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 154, 261-275 (1998)
51. A. D. Smith, A. D., Kozlowski, M. C. Bohn and M. J. Zigmond: Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats. Exp Neurol. 193, 420-426 (2005)
52. A. Natsume, M. Mata, J. Goss, S. Huang, D. Wolfe, T. Oligino, J. Glorioso and D.J., Fink: Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp Neurol 169, 231-238 (2001)
53. M. Sun, L. Kong, X. Wang, X. G. Lu, Q. Gao and A. I. Geller: Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res. 1052, 119-129 (2005)
54. M. E. Emborg, J. Moirano, J. Raschke, V. Bondarenko, R. Zufferey, S. Peng, A. D. Ebert, V. Joers, B. Roitberg, J. E. Holden, J. Koprich, J. Lipton, J. H. Kordower: and P.A ebischer:. Response of aged parkinsonian monkeys to in vivo gene transfer of GDNF. Neurobiol. Dis. 36, 303-311 (2009)
55. D. J. Creedon, M. G. Tansey, R. H. Baloh, P. A. Osborne, P. A. Lampe, T. J. Fahrner, R. O. Heuckeroth, J. Milbrandt and E. M. Johnson Jr: Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic factor in sympathetic neurons. Proc Natl Acad Sci U S A 94,7018-7023 (.1997)
56. B. A. Horger, M. C. Nishimura, M. P. Armanini, L. C. Wang, K. T. Poulsen, C. Rosenblad, D. Kirik, B. Moffat, L. Simmons, E. Johnson Jr, J. Milbrandt, A. Rosenthal, A. Bjorklund, R. A. Vandlen, M. A. Hynes and H. S. Phillips: Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18, 4929-4937 (1998)
57. M. Gasmi, E. P. Brandon, C. D. Herzog, A. Wilson, K. M. Bishop, E. K.Hofer, J. J. Cunningham, M. A. Printz, J. H. Kordower, R. T. Bartus: AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis 2, 67-76 (2007)
58. M. Gasmi, C. D. Herzog, E. F. Brandon, J. J. Cunningham, G. A. Ramirez E. T. Ketchum, R. T. Bartus: Striatal delivery of neurturin by CERE-120, an AAV2 vector for the treatment of dopaminergic neuron degeneration in Parkinson's disease. Mol Ther, 15, 62-68 (2007)
59. C. D. Herzog, L. Brown, D. Gammon, B. Kruegel, R. Lin, A. Wilson, A. Bolton, M. Printz, M. Gasmi, K. M. Bishop, J. H. Kordower and R. T. Bartus: Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery 64, 602-612 (2009)
60. C. D. Herzog, B. Dass, M. Gasmi, R. Bakay, J. E. Stansell, M. Tuszynski, K. Bankiewicz, E. Y. Chen, Y. Chu, K. Bishop, J, H. Kordower and R. T. Bartus: Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther 16, 1737-1744 (2008)
61. C. D. Herzog, B. Dass, J. E. Holden, J. Stansell 3rd, M. Gasmi, M. H. Tuszynski, R. T. Bartus and J. H. Kordower: Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord 22, 1124-1132 (2007)
62. J. H. Kordower, C. D. Herzog, B. Dass, R. A. Bakay, J. Stansell 3rd, M. Gasmi and R. T. Bartus: Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol 60, 706-715(2006)
63. J. H. Kordower, S. Palfi, E. Y. Chen, S. Y.Ma, T. Sendera, E. J. Cochran, E. J. Mufson, R. Penn, C. G. Goetz and C. D. Comella: Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46, 419-424 (1999)
64. J. T. Slevin, D. M. Gash, C. D. Smith, G. A. Gerhardt, R. Kryscio, H. Chebrolu, A. Walton, R. Wagner and A. B. Young: Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg 106, 614-620 (2007)
65. S, S. Gill, N. K. Patel, G. R. Hotton, K. O. Sullivan, R. McCarter, M. Bunnage, D. J. Brooks, C. N. Svendsen and P. Heywood, Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9, 589-595 (2003)
66. S. Love, P. Plaha, N. K. Patel, G.R.Hotton, D.J.Brooks and Gill SS. Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11, 703-704 (2005)
67. R. T. Bartus, C.D. Herzog, K. Bishop, J. M. Ostrove, M. Tuszynski, J. H. Kordower and M. Gasmi: Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAVNTN) as one reference point. Parkinsonism Relat Disord. 3, S469-S477 (2007)
68. W. J. Marks Jr, J. L. Ostrem, L. Verhagen, P. A. Starr, P. S. Larson, R. A. Bakay, R. Taylor, D. A. Cahn-Weiner, A. J. Stoessl, C. W. Olanow and R, T, Bartus: Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7, 400-408 (2008)
69. S. Ramaswamy, K. E. Soderstrom and J. H. Kordower: Trophic factors therapy in Parkinson's disease. Prog. Brain Res. 175, 201-216 (.2009)
70. G. Nikkhah, M. G. Cunningham, R. McKay and A. Björklund: Dopaminergic Microtransplants into the Substantia-Nigra of Neonatal Rats with Bilateral 6-Ohda Lesions .1. Evidence for Anatomical Reconstruction of the Nigrostriatal Pathway. J Neurosci 15, 3548-3561(1995)
71. H. Braak and K. Del Tredici: Assessing fetal nerve cell grafts in Parkinson's disease. Nat Med 14, 483-485 (2008)
72. L. H. Thompson, S. Grealish, D. Kirik and A. Björklund: Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur J Neurosci 30, 625-638 (2009)
73. B. C.Blanchard, B.M.Pelka and J.R.Sladek Jr: A strategy for nigrostriatal tract reconstruction in response to striatal trophic factors. Cell Transplantation 19,332-332 (2010)
74. E. O.Backlund, P. O. Granberg, B. Hamberger, E. Knutsson, A. Mårtensson, G. Sedvall, A. Seiger and l. Olson: Transplantation of adrenal medullary tissue to striatum in parkinsonism. First clinical trials. J Neurosurg 62, 169-173 (1985)
75. P. Brundin, O. Pogarell, P. Hagell, P. Piccini, H. Widner, A. Schrag, A. Kupsch, L. Crabb, P. Odin, B. Gustavii, A. Björklund, D. J. Brooks, C. D. Marsden, W. H.Oertel, N. P. Quinn, S, Rehncrona and O. Lindvall Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 123, 1380-1390 (2000)
76. A. K. Agrawal, R. K. Chaturved, S. Shukla, K. Seth, S. Chauhan, A. Ahmad and P. K. Seth:. Restorative potential of dopaminergic grafts in presence of antioxidants in rat model of Parkinson's disease. J Chem Neuroanat 28, 253-264 (2004)
77. C. W. Olanow, C. G. Goetz, J. H. Kordower, A. J. Stoessl, V. Sossi, M. F. Brin, K. M. Shannon;, G. M. Nauert, D. P. Perl, J. Godbold and T, B. Freeman: A Double-blind Controlled Trial of Bilateral Fetal Nigral Transplantation in Parkinson's Disease. Ann Neurol 54, 403-414 (2003)
78. M. S. Cho, Y. E. Lee, J. Y. Kim, S. Chung, Y. H. Cho, D. S. Kim, S. M. Kang;, H. Lee, M. H. Kim, J. H. Kim, J. W. Leem, S. K. Oh, Y. M. Choi, D. Y. Hwang, J. W. Chang and D. W. Kim: Highly efficient and largescale generation of functional dopamine neurons from human embryonic stem cells. Proc Natl Acad Sci USA 105, 3392-3397 (2008)
79. N. S. Roy, C. Cleren, S. K. Singh, L. Yang, M. F. Beal and S. A. Goldman: Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 12, 1259-1268 (2006)
80. K. Takahashi, K. Tanabe, M. Ohnuki, M. Narita, T. Ichisaka, K. Tomoda and S. Yamanaka: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131, 861-72 (2007)
81. M. Wernig, J. P. Zhao, J. Pruszak, E. Hedlund, D. Fu, F. Soldner, M. .Broccoli, Constantine-Paton, O. Isacson and R. Jaenisch: Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 105, 5856-5861 (2008)
82. A. E. Rosser, R. Zietlow and S. B. Dunnett: Stem cell transplantation for neurodegenerative diseases. Curr Opin. Neurol 20, 688-692 (2007)
83. O. Lindvall and Z. Kokaia: Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. Trends Pharmacol. Sci. 30, 260-267 (2009)
84. E. Hedlund and T. Perlmann: Neuronal cell replacement in Parkinson's disease. J.Intern. Med. 266, 358-371 (2009)
85. G. Nikkhah, C. Bentlage, M. G. Cunningham and A. Björklund: Intranigral fetal dopamine grafts induce behavioral compensation in the rat Parkinson model. J Neurosci 14, 3449-3461 (1994)
86. G.Nikkhah, M.G.Cunningham, A.Jödicke, U.Knapp and A.Björklund: Improved graft survival and striatal reinnervation by microtransplantation of fetal nigral cell suspensions in the rat Parkinson model. Brain Res 633, 133-143 (1994)
87. A. Gaillard, M. Decressac, I. Frappe, P. O. Fernagut, L. Prestoz, S. Besnard and M. Jaber Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants. Neurobiol Dis. 35, 477-488 (2009)
88. Y. Wang, L. T. Tien, P. A. Lapchak and B. J. Hoffer: GDNF triggers fiber outgrowth of fetal ventral mesencephalic grafts from nigra to striatum in 6-OHDA-lesioned rats. Cell Tissue Res 286, 225-233. (1996)
89. S. B. Dunnett, D. C. Rogers and S. J. Richards: Nigrostriatal reconstruction after 6-OHDA lesions in rats: combination of dopamine-rich nigral grafts and nigrostriatal "bridge" grafts. Exp Brain Res 75, 523-535 (1989)
90. J. E. Brecknell, J. S. Du, E. Muir, P. S. Fidler, M. L. Hlavin;, S. B. Dunnett and J. W. Fawcett: Bridge grafts of fibroblast growthfactor-4-secreting schwannoma cells promote functional axonal regeneration in the nigrostriatal pathway of the adult rat. Neuroscience 74, 775-784 (1996)
91. M. J. Wilby, S. R. Sinclair, E. M. Muir, R. Zietlow, K.H. Adcock, P. Horellou, J H. Rogers, B. Dunnett and J. W. Fawcett, A glial cell line-derived neurotrophic factor-secreting clone of the Schwann cell line SCTM41 enhances survival and fiber outgrowth from embryonic nigral neurons grafted to the striatum and to the lesioned substantia nigra. J Neurosci.19, 2301-2312 (1999)
92. Y. Chiang, M. Morales, F. C. Zhou, C. Borlongan, B. J. Hoffer and Y. Wang: Fetal intra-nigral ventral mesencephalon and kidney tissue bridge transplantation restores the nigrostriatal dopamine pathway in hemi-parkinsonian rats. Brain Res 889, 200-207 (2001)
93. C. Zhang, Y. Jin, K. S. Ziemba, A. M. Fletcher, B. Ghosh, E. Truit, D. M. Yurek and G. M. Smith: Long distance directional growth of dopaminergic axons along pathways of netrin-1 and GDNF. Exp Neurol. 250C, 156-164 (2013)
94. D. M. Gash, Z. Zhang, A. Ovadia, W. A. Cass, A. Yi, L. Simmerman, D. Russell, D. Martin, P. A. Lapchak, F. Collins, B. J. Hoffer and G. A. Gerhardt: Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380, 252-255 (1996)
95. R. Grondin and D. M. Gash: Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease. 245, 35-42 (1998)
96. D. Kirik, B. Georgievska and A. Björklund: Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci 7, 105-110 (2004)
97. A. P. Kells, J. Eberling, X. Su, P. Pivirotto, J.Bringas, P.Hadaczek, W. C. Narrow, W. J. Bowers, H. J. Federoff, J. Forsayeth, K. S. Bankiewicz, Regeneration of the MPTP-Lesioned Dopaminergic System after Convection-Enhanced Delivery of AAV2-GDNF. J Neurosci 30, 9567-9577 (2010)
98. L. F. Lin, D. H. Doherty, J. D. Lile, S. Bektesh and F. Collins: GDNF - a Glial-Cell Line Derived Neurotrophic Factor for Midbrain Dopaminergic-Neurons. Science 260, 1130-1132 (1993)
99. M. Johansson, M. Friedemann, B. Hoffer and I. Strömberg: Effects of glial cell line-derived neurotrophic factor on developing and mature ventral mesencephalic grafts in oculo. Exp Neurol 134, 25-3 (1995)
100. C. Rosenblad, D. Kirik and A. Björklund: Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants. Neuroreport 10: 1783-1787 (1999)
101. D. M. Yurek: Glial cell line-derived neurotrophic factor improves survival of dopaminergic neurons in transplants of fetal ventral mesencephalic tissue. Exp Neurol 153, 195-202 (1998)
102. F. Ledda, G. Paratcha and C. F. Ibanez: Target-derived GFRalpha1 as an attractive guidance signal for developing sensory and sympathetic axons via activation of Cdk5. Neuron 36, 387-401(2002)
103. S. Jing, D. Wen, Y. Yu, P. L. Holst, Y. Luo, M. Fang, R. Tamir, L. Antonio, Z. Hu, R. Cupples, J. C.Louis, S. Hu, B. W. Altrock and G. M. Fox: GDNF-induced activation of the Ret proteintyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 85, 1113-1124 (1996)
104. G. Paratcha and F. Ledda: GDNF and GFR-alpha: a versatile molecular complex for developing neurons. Trends Neurosci 31, 384-391(2008)
105. J. Nielsen, K. Gotfryd, S. Li, N. Kulahin, V. Soroka, K. K. Rasmussen, E. Bock and V. Berezin: Role of Glial Cell Line-Derived Neurotrophic Factor (GDNF)-Neural Cell Adhesion Molecule (NCAM) Interactions in Induction of Neurite Outgrowth and Identification of a Binding Site for NCAM in the Heel Region of GDNF. J Neurosci 29, 11360-11376 (2009)
106. M. S. Airaksinen and M. Saarma: The GDNF family: signalling, biological functions and therapeutic value. Nat Rev Neurosci. 3, 383-94 (2002)
107. L. Lin, Y. Rao and O. Isacson: Netrin-1 and slit-2 regulate and direct neurite growth of ventral midbrain dopaminergic neurons. Mol Cell Neurosci 28, 547-555 (2005)
108. T. E. Kennedy, T. Serafini, J. R.de la Torre and M. Tessier-Lavigne: Netrins are diffusible chemotropic factors for commissural axons in the embryonic spinal cord. Cell 78, 425-435 (1994)
109. F. J. Livesey and S. P. Hunt: Netrin and netrin receptor expression in the embryonic mammalian nervous system suggests roles in retinal, striatal, nigral, and cerebellar development. Mol Cell Neurosci 8, 417-429 (1997)
110. K. T. Yee, H. H. Simon, M. Tessier-Lavigne and D. M. O'Leary: Extension of long leading processes and neuronal migration in the mammalian brain directed by the chemoattractant netrin-1. Neuron 24, 607-622 (1999)
111. E. W. Dent, A. M. Barnes, F. Tang and K. Kalil: Netrin-1 and semaphorin 3A promote or inhibit cortical axon branching, respectively, by reorganization of the cytoskeleton. J Neurosci 24, 3002-3012 (2004)
112. K. L Guan and Y. Rao: Signalling mechanisms mediating neuronal responses to Guidance cues. Nat Rev Neurosci 4, 941-956 (2003)
113. S. W. Moore, M. Tessier-Lavigne and T. E. Kennedy: Netrins and their receptors. Axon Growth and Guidance Adv Exp Med Biol 621, 17-31(2007)
114. A. Ly, A. Nikolaev, G. Suresh, Y. Zheng, M. Tessier-Lavigne, and E. Stein:. DSCAM is a netrin receptor that collaborates with DCC in mediating turning responses to netrin-1. Cell 133: 1241-1254 (2008)
115. G. Liu, W. Li, L. Wang, A. Kar, K. L. Guan, Y. Rao and J.Y.Wu: DSCAM functions as a netrin receptor in commissural axon path finding. Proc Nat Acad Sci USA 106, 2951-2956 (2009)
116. K. Keino-Masu, M. Masu, L. Hinck, E. D. Leonardo, S. S. Chan, J. G. Culotti and M. Tessier-Lavigne: Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell 87, 175-185 (1996)
117. B. Xu, J. S. Goldman, V. V. Rymar, C. Forget, P.S.Lo, S.J.Bull, E.Vereker, P.A.Barker, L. E. Trudeau, A. F. Sadikot and T. E. Kennedy: Critical roles for the netrin receptor deleted in colorectal cancer in dopaminergic neuronal precursor migration, axon guidance, and axon arborization. Neuroscience 169, 932-949 (2010)
118. E. F. Govek, S. E. Newey and L. Van Aelst: The role of the Rho GTPases in neuronal development. Genes & Development 19, 1-49 (2005)
119. J. Round and E. Stein: Netrin signaling leading to directed growth cone steering. Curr Opin Neurobiol 17, 15-21 (2007)
120. L. Q. Luo: Actin cytoskeleton regulation in neuronal morphogenesis and structural plasticity. Annual Review of Cell and Developmental Biology 18:601-635 (2002)
121. A. B. Huber, A. L. Kolodkin, D. D. Ginty and J. F. Cloutier: Signaling at the growth cone: Ligand-receptor complexes and the control of axon growth and guidance. Annual Review of Neuroscience 26: 509-563. (2003)
122. P. B. Osborne, G. M. Halliday, H. M. Cooper and J. R. Keast: Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience 131, 671-681(2005)
123. C. Manitt, C. Labelle-Dumais, C. Eng, A. Grant, A. Mimee, T. Stroh and C. Flores: Peri-pubertal emergence of UNC-5 homologue expression by dopamine neurons in rodents. PLoS One 5, e11463 (2010)
124. O. Lindvall and A.Bjorklund: Cell therapy in Parkinson's disease. NeuroRx 1, 382-393 (2004)
125. O. Lindvall and A.Bjorklund, Cell therapeutics in Parkinson's dis-ease. Aerotherapeutics 8, 539-548 (2011)
126. A. Gaillard and M. Jaber: .Rewiring the brain with cell transplantation in Parkinson's disease. Trends Neurosci 34,124-133 (2011)
127. L. H. Thompson, S. Grealish, D. Kirik and A' Björklund: Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur J Neurosci 30, 25-638 (2009)
128. S. R. Kim, X. Chen, T.F. Oo, T. Kareva, O. Y. arygina, C. Wang, M. During, N. Kholodilov and R. E. Burke: Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration. Ann Neurol, 70, 110-120 (2011) Stroke